Boston Scientific said in a regulatory filing that it has been permitted by the FDA to resume shipments of its remaining five heart devices after the agency approved the manufacturing changes the company made to the products. The affected devices include Livian cardiac resynchronization therapy defibrillator and Confient implantable cardioverter defibrillator.

Related Summaries